Showing 2451-2460 of 3039 results for "".
- Aramis Biosciences Completes Enrollment of its Phase 2 Clinical Trial Evaluating A197 for the Treatment of Dry Eye Diseasehttps://modernod.com/news/aramis-biosciences-completes-enrollment-of-its-phase-2-clinical-trial-evaluating-a197-for-the-treatment-of-dry-eye-disease/2481219/Aramis Biosciences announced the completion of enrollment in its phase 2 proof of concept clinical trial evaluating A197, a novel, first-in-class, topical immunomodulatory agent for the treatment of dry eye disease. “We are very pleased to have completed the enrollment of our phas
- Alimera Announces Reimbursement of Uveitis Indication Granted for Iluvien in the Czech Republichttps://modernod.com/news/alimera-announces-reimbursement-of-uveitis-indication-granted-for-iluvien-in-the-czech-republic/2481212/Alimera Sciences announced that Alimera Sciences Europe Limited, its Ireland-based European subsidiary, has been granted reimbursement for Iluvien (fluocinolone acetonide intravitreal implant) 0.19 mg sustained release intravitreal implant for noninfectious uveitis, through its distribu
- BioTissue Completes Name Changehttps://modernod.com/news/biotissue-completes-name-change/2481211/BioTissue Holdings announced the completion of its name change from TissueTech. The change is part of a corporate-wide branding initiative launched earlier this year to better represent the company’s entire portfolio and pipeline of products. Pursuant to the name change, the former Tis
- Nicox Reports Achieving Primary Objective in Mont Blanc, the First Phase 3 Glaucoma Trial for NCX 470https://modernod.com/news/nicox-reports-achieving-primary-objective-in-mont-blanc-the-first-phase-3-glaucoma-trial-for-ncx-470/2481209/Nicox SA announced that once daily dosing of NCX 470 0.1% met the primary objective of noninferiority in lowering IOP compared to the standard of care, latanoprost 0.005%, in the 691-patient Mont Blanc phase 3 clinical trial in patients with open-angle glaucoma or ocular hypertension.</
- Alcon to Celebrate 75 Years and Showcase Contact Lens Innovations at #Academy22https://modernod.com/news/alcon-to-celebrate-75-years-and-showcase-contact-lens-innovations-at-academy22/2481197/Alcon will feature a host of innovations across its portfolio of products along with pertinent practice takeaways at the American Academy of Optometry Annual Meeting (#Academy22) in San Diego, California, on October 27, 2022. The meeting coincides with Alcon’s Diamond Jubilee, celebrating 7
- Nanodropper Launches 2022 Give the Gift of Vision Campaign to Support Global Access to Eye Carehttps://modernod.com/news/nanodropper-launches-2022-give-the-gift-of-vision-campaign-to-support-global-access-to-eye-care/2481193/Nanodropper launched its "2022 Give the Gift of Vision" program, an effort to donate 1,000 Nanodropper adaptors to at-need patients in the United States and its global nonprofit partners—designed to deliver better access to vision-saving care in low resource settings in
- Study: Digital Home Monitoring Shows Unique Predictive Value in Disease Progression for AMD Patientshttps://modernod.com/news/study-digital-home-monitoring-shows-unique-predictive-value-in-disease-progression-for-amd-patients/2481190/Notal Vision reported the publication of the second report of the "Analysis of Long-term visual Outcomes of ForeseeHome Remote Telemonitoring (ALOFT)" study results in Ophthalmology Retina. The 10-year retrospective study details the importance of digital remote monitor
- OcuTerra Reports Publication of OTT166 Safety and Biological Activity Data From Phase 1b Study in Diabetic Eye Diseasehttps://modernod.com/news/ocuterra-reports-publication-of-ott166-safety-and-biological-activity-data-from-phase-1b-study-in-diabetic-eye-disease/2481180/OcuTerra Therapeutics announced the publication of a paper titled “The Safety and Biological Activity of OTT166, a Novel Topical Selective Integrin Inhibitor for the Treatment of Diabetic Eye Disease: A Phase 1b Study” in Ophthalmic Surgery, Lasers and Imaging Retina (
- Researchers Discover New Molecular Driver of Retinoblastomahttps://modernod.com/news/researchers-discover-new-molecular-driver-of-retinoblastoma/2481163/Despite decades of medical advances, children who develop the pediatric eye cancer retinoblastoma often lose their vision or an eye due to a lack of specific, targeted therapies and a poor molecular understanding of the cancer. Now researchers at UT Southwestern and the University of Miami have <
- New Study Shows People with Glaucoma are at Significant Risk of Alzheimer’s Diseasehttps://modernod.com/news/new-study-shows-people-with-glaucoma-are-at-significant-risk-of-alzheimers-disease/2481142/A large, nationwide study from Taiwan shows that people with a specific type of glaucoma, called normal-tension glaucoma, are at high risk for developing Alzheimer&r